The findings identify possible targets for future therapies for ribosomopathies, childhood disorders that lead to bone marrow failure (BMF).

CHOP researchers have developed a gene therapy vector for sickle cell disease and other blood disorder that is potentially superior to competitors.

CHOP researchers identified an in vivo role for activated protein C (APC), which could potentially be exploited for future hemophilia A treatments.

CHOP researchers found the elevated biomarker in all children who tested positive for SARS-CoV-2, whether they were symptomatic for COVID-19 or not.

CHOP researchers show convalescent plasma appears to be a safe and possibly effective treatment for children with life-threatening cases of COVID-19.

New treatment developed by CHOP researchers poised to improve sepsis outcomes.

The US Food and Drug Administration has granted accelerated approval to two novel drugs to treat sickle cell disease.

The US Food and Drug Administration has approved two new breakthrough therapies for patients with sickle cell disease (SCD), and we believe both may enhance the treatment of our patients here at CHOP.

Stefano Rivella, PhD, an expert in creating the next-generation lentiviral vectors for the cure of hemoglobinopathies including sickle cell disease (SCD), as well as a leader in the discovery of erythroid and iron disorders including beta-thalassemia, has led three new published studies that make significant contributions to the scientific body of literature regarding red blood cells, and how manipulating the production of red cells can lead to the development of new disease-modifying therapies.

Dr. Oved brings deep expertise to the group, having completed scientific and clinical training that included tenures as a Fulbright Fellow with the Weizmann Institute in Israel, the NYU School of Medicine with two years as a Howard Hughes Medical Fellow, followed by a residency in Pediatrics at NYP Weill Cornell Medical College.